Media headlines about Auris Medical (NASDAQ:EARS) have trended somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Auris Medical earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 46.7658312561268 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Auris Medical (NASDAQ EARS) traded down $0.01 during trading hours on Friday, hitting $0.50. 419,288 shares of the company were exchanged, compared to its average volume of 851,862. The company has a debt-to-equity ratio of -14.04, a current ratio of 1.86 and a quick ratio of 1.86. The stock has a market cap of $23.04, a PE ratio of -0.76 and a beta of 0.61. Auris Medical has a 1 year low of $0.38 and a 1 year high of $1.39.

Auris Medical (NASDAQ:EARS) last posted its quarterly earnings data on Tuesday, November 28th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.05.

Separately, Zacks Investment Research cut shares of Auris Medical from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th.

COPYRIGHT VIOLATION WARNING: “Auris Medical (EARS) Earning Somewhat Positive News Coverage, Report Shows” was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at

Auris Medical Company Profile

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Insider Buying and Selling by Quarter for Auris Medical (NASDAQ:EARS)

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with's FREE daily email newsletter.